Egalet to Present at Several Upcoming Scientific Conferences

WAYNE, Pa., March 7, 2017 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that representatives from Egalet will be participating in several upcoming scientific industry conferences this month. The presentations are as follows:

• CBI's Abuse-Deterrent Formulations Summit 
  March 8, 2017 at 9:15 a.m. ET
  Embassy Suites by Hilton, Alexandria, VA
  Karsten Lindhardt, Ph.D., senior vice president research and development, and Torben Elhauge, senior science specialist at Egalet, will present a case study called "Design and Interpretation of Category 1 Data."
  For more information visit, http://www.cbinet.com/conference/pc17298
                                                       
• 2nd Category 1 Focus Group Meeting 
  March 9, 2017
  Embassy Suites by Hilton, Alexandria, VA
  Egalet, a member of the Cross Company Abuse Liability Council (CCALC), is hosting the meeting.
  For more information visit, http://www.cat1focusgroup.com/
                                                        
  • 8:40 a.m.: Dr. Lindhardt will present "Challenges in standardization of Category 1 studies."
                                                         
  • 10:30 a.m.: Mr. Elhauge will participate in a panel discussion titled, "Areas of Standardization and Forming Working Groups for a Coming Standardization Meeting."
                                                         
  • 2:40 p.m.: Dr. Lindhardt also will participate in a panel discussion titled, "Can Abuse-Deterrent Equivalence be Established in a Meaningful Way from In Vitro Data Alone?"                                                     
    
    

• 6th ExL Drug Formulation, Solubility and Bioavailability Summit
  March 28, 2017 at 10:30 a.m.
  Hilton Boston Back Bay, Boston, MA
  Dr. Lindhardt will present "New Technological Approaches to Improving Oral Drug Delivery by Injection Molding."
  For more information visit, www.exlevents.com/bioavailability

About Egalet
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has three approved products: ARYMO™ ER (morphine sulfate) extended-release tablets for oral use only –CII, developed using Egalet's proprietary Guardian™ Technology, OXAYDO^® (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX^® (ketorolac tromethamine) Nasal Spray. Using Guardian Technology Egalet is developing a pipeline of clinical-stage, product candidates including Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. For full prescribing information on ARYMO ER, including the boxed warning and medication guide, please visit arymoer.com. For full prescribing information on SPRIX, including the boxed warning and medication guide, please visit sprix.com. For full prescribing information on OXAYDO, please visit oxaydo.com.  For additional information on Egalet, please visit egalet.com.

Safe Harbor
Statements included in this press release (including but not limited to upcoming milestones) that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of Egalet's clinical trials, including the timely recruitment of trial subjects and meeting the timelines therefor; Egalet's ability to obtain regulatory approval of Egalet's product candidates; Egalet's ability to maintain the intellectual property position of Egalet's products and product candidates; Egalet's ability to identify and reliance upon qualified third parties to manufacture its products; Egalet's ability to service its debt obligations; Egalet's ability to find and hire qualified sales professionals; the receptivity in the marketplace and among physicians to Egalet's products; the success of products which compete with Egalet's that are or become available; general market conditions; and other risk factors described in Egalet's filings with the United States Securities and Exchange Commission. Egalet assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

Media and Investor Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: [email protected]
Tel: 917-432-9275

SOURCE Egalet Corporation

Related Links

http://www.egalet.com